Oxford Biomedica to manufacture vectors for Boehringer Ingelheim

By The Science Advisory Board staff writers

April 6, 2021 -- Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.

Under the terms of the development and supply agreement, Oxford Biomedica said it intends to manufacture good manufacturing practice (GMP) batches for Boehringer Ingelheim to support the development of viral vectors. The agreement also allows for Oxford Biomedica to manufacture and supply viral vectors in the future, according to the company.

Oxford Biomedica and its subsidiaries have built LentiVector, a lentiviral vector delivery platform that they use to develop in vivo and ex vivo products both internally and with partners.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?